At present, EGFR TKIs have been approved for the treatment of sensitizing EGFR mutations, exon 19 deletions (Del19) and the L858R point mutation, which account for about 85% of observed EGFR mutations in NSCLC.102. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.